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Introduction
Epilepsy, a global health problem, is a brain cortex disorder 
characterized by an enduring predisposition to generate epileptic 
seizures in any age, sex and geographical regions without racism or 
socioeconomically class discrimination. It is also associated with a 
personal, familial, economical and psychosocial burden (1, 2). Up to 
10% of the people worldwide experience at least one epileptic seizure 
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during their normal lifespan (3). It is estimated 
that 50-70 million of world’s population live with 
epilepsy. According to the studies, approximately 
80-90% of these patients live in developing 
countries such as Iran (4–7). 
In a meta-analysis and systematic review study, 
the prevalence of epilepsy in Iran estimated nearly 
5 %.It means that 4 million epileptic people live in 
Iran, considering a total 80 million of population 
.The authors notified that the result is much higher 
than reported prevalence in other countries (8).
Although antiseizure drugs (ASDs) have proven 
efficacy in treatment of epilepsy, unfortunately 
they are not always effective. Approximately 30-
33% of patients have drug resistant epilepsy (DRE) 
even when they are treated with multiple ASDs (9, 
10). Current International League Against Epilepsy 
(ILAE) defines Drug-resistant epilepsy (also 
named intractable epilepsy or refractory epilepsy) 
as “failure of adequate trials of two tolerated, 
appropriately chosen and used antiepileptic 
drugs schedules (whether as monotherapy or 
in combination) to achieve sustained seizure 
freedom” (10, 11). DRE is a challenging aspect of 
children epilepsy treatment despite development 
of new generation of ASDs. Thus, a need for 
additional therapeutic options is inevitable (12, 
13).  There are many available nonpharmacologic 
proven therapies for DRE. Dietary treatments are 
one of these therapeutic options (14).
 In this review, we will address the different 
features of pediatric epilepsy dietary therapies in 
Iran including history of epilepsy in ancient Iran, 
utilization, effectiveness, side effects, tolerability, 
and acceptability as well as ongoing and future 
programs.
Historical Perspectives
The history of epilepsy
A) Epilepsy in the ancient world
The history of epilepsy is as old as the history of 
humanity in the world (15).The stone tablets of the 
Sakikku (meaning “all diseases”), a Babylonian 
text compiled around 1000 BC, is the first known 
detailed description of various seizure types. 
The Sakikku refers to the epilepsy with the 
terms ‘antasubba’ and ‘miqtu’. The translated 
Babylonian text describes epilepsy features in 
the words such as unilateral and bilateral fits, the 
epileptic cry, the defecation incontinence, simple 
and complex epileptic seizures, the epileptic aura 
and narcolepsy (16).The Babylonians believed 
that epilepsy is secondary to supernatural powers 
and patients with epilepsy considered as a “person 
possessed by a particular demon or evil spirit” (17). 
The “falling sickness” is a translation of Sumerian 
term referring to descriptions of seizures (18).
There is additional ancient reports about epilepsy 
descriptions including:
1- “Hand of sin, god of the moon” in Mesopotamian 
writings as the Akkadian texts, dating back to 
2000-4000 B.C.
2- Loss of consciousness in the ancient Indian 
medicine texts, dating back to 1500-4500 B.C.
3- The Edwin Smith surgical papyrus, ancient 
Egyptian medical texts, refers to epileptic 
convulsions in at least five cases in 1700 B.C.
4- The word ‘epilepsy’ originates etymologically 
from the Greek word “epilambanein”, which means 
‘to seize, possess, or afflict and repeated attacks’. 
The disease was initially called sacred, because 
of the belief for its divine origin. Heracletus of 
Ephesus (535–475 B.C) referred the disease to the 
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term ‘sacred disease’ with the hereditary nature, 
but not for describing epileptic seizures. The first 
formal description of epilepsy as a disease should 
be attributed to the father of medicine, Hippocrates 
of Kos, in his classic treatise on the sacred disease 
(19).
B) Epilepsy in the ancient Iran 
The history of medicine in Iran is as old as the 
Persian civilization (20) when nearly 2700 years 
ago, two groups of Aryans, the Medes and the 
Persians, immigrated and settled in the Iranian 
plateau to the East of the Zagros Mountains and 
about two centuries later united and formed the 
Persian Empire (21).One of the earliest reports 
about epilepsy in Iranian people traced back to 
Herodotus of Hallicarnassus (484 - 425 B.C.), 
the father of history, in the third book of his work 
The Histories (Thaleia).He described in details 
the epileptic phenomena of the  Persian (Iranian) 
King Cambyses II, son of Cyrus. According to 
Herodotus, King’s bizarre and aggressive behavior 
could be attributed to either the retribution of an 
aggrieved god or the so-called ‘sacred disease 
(22, 23). Generally, the medical history of ancient 
Persia and subsequently epilepsy related reports 
can be divided into three distinct periods.
1- Avestan or Zoroastrian Medicine
The Avesta, a collection of Zoroastrian holy 
writings, is the first Persian text that includes some 
documents of ancient Iranian medicine addressing 
the health and sickness. It was probably compiled 
during the 6th Century B.C., but the precise date is 
not determined. Apart from this Avestic reference, 
no other sources addressed to the Persian attitudes 
about epilepsy in those times (24, 25).
2- The Sassanian Era
The Persian king, Shapur I (242 to 272 AD) 
founded the city of Gondi-Shapur or Jundishapur 
on the site of present-day Ahwaz (26). Head of 
king Shapur II (Sasanian dynasty, 4th century 
CE) made Gondi-Shapur the capital of his empire 
(27). Gondi-Shapur became known as the ‘city 
of Hippocrates’ and the intellectual center of the 
Sasanian Empire. Its library contained 400 000 
books and on its portal was engraved, ‘Knowledge 
and virtue are superior to sword and power’ (28). 
The academy of Gondi-Shapur offered training 
in medicine, philosophy, theology and science. 
Scholars from other countries studied different 
fields including medicine at the university (29). In 
this period, the Vendidad, the fourth section of the 
Avesta, script into which it was transcribed during 
the Sasan period, in the 6th Century A.C. (30). 
3- Medieval Islamic Period
In this period, epilepsy was one of important disease 
in the field of traditional Iranian neuroscience. 
The two major Iranian Hakims (practitioners), 
Muhammad ibn Zakariya al-Razi, known to the 
West as Rhazes (865-925 AD), and Ibn Sina, known 
as Avicenna (980-1037), considered epilepsy as a 
medical illness(31,32). “Qanoon fel teb of Avicenna 
or The Canon” and “Kitab al-Hawi of Razi or 
Continens” were reference texts in the western 
medical education from the 13th to the 18th centuries 
(33,34). In The Canon of Medicine (c. 1025), 
Avicenna described numerous mental conditions, 
including epilepsy, paralysis, stroke, vertigo, 
tremor, hallucination, nightmare, insomnia, mania, 
and dementia (35). Razi is considered as the father 
of pediatrics and a pioneer of neurosurgery and 
ophthalmology. In the “Continens”, he described 
three cases of epilepsy treated by him (36).During 
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the epileptic attacks, the patient fall to the ground, 
cry and froth at the mouth, Razi stated. In some 
patients, bladder or bowel incontinence may occur 
(37). 
Ibn Sina, the “Prince of Doctors”, was scientific 
and rational in his treatment of epilepsy. He was 
the first person to coin the term “epilepsy”, using 
a passive Latin verb. (38).With regard to epilepsy, 
Avicenna also adopted Galen’s theories, but he 
integrated them with some of his own original 
intuitions. In his Canon of Medicine, Ibn Sina 
describes epilepsy in comprehensive detail with its 
“variants and types along with clinical presentations 
and etiology”. He, also, offers therapeutic options 
for treatment of epilepsy .According to Avicenna, 
some of epilepsy features are following: 
1-The lower ventricle in the brain, is the exact 
origin of spasms because the initial presentations 
of epileptic attack involve the sense of sight and 
hearing as well as facial muscles and eyelids. 
2- Epileptic contractions are provoked by the 
presence of an unhealthy humor of which the body 
is trying to slough. 
3- Epileptic contractions are originated from the 
nerves in both longitudinal and latitudinal sense.
4- Melancholy is a more serious form of epilepsy 
with a distressing effect (10,39).
The history of epilepsy dietary treatment
A) Ancient period
In the past, practitioners advocated many dietary 
treatments for epilepsy including either overuse 
or abstain from nourishments. However, fasting 
as a treatment for seizures was less recognized. 
Fasting is the only therapeutic measure against 
epilepsy recorded in the Hippocratic collection; 
complete abstinence from foods and drinks causes 
the effective cure of epilepsy. Fasting, as a therapy 
for seizures, was documented in biblical times. In 
a quotation from the King James Version of the 
Bible, Mark relates the story of Jesus curing an 
epileptic boy (15).
The Iranian practitioners notified the importance 
of food and diet in treatment of epilepsy (31).
One of these, Avicenna, suggested his theory 
on relationship between diseases and dietary 
regiment almost 1000 years ago: most illnesses 
are exclusively secondary to sustained mistakes of 
diet. This theory is a fundamental concept in the 
Islamic medicine. Based on ancient personalized 
medicine, he prescribed a long list of the herbal 
and pharmacological recipes and dietary rules for 
treatment of epilepsy (39, 41).In the Canon, some 
of his major consideration dedicated to treatment 
of epilepsy can be considered as the first ancient 
epilepsy guideline:
1-The patients with epilepsy must avoid not only 
excessive eating but also some foods such as 
cow and sheep meat, fish, onion, garlic, celery, 
cauliflower, and carrot.
2-The patients may need surgery. The “operating 
therapeutic model” is being followed for centuries, 
not only in Iran but also throughout the world. 
3-Infants and young children with epilepsy should 
be protected from excessively shrill noises.
4-Epileptic children should not be exposed to 
intensely bright lights.
5- The patients with epilepsy must avoid hot and 
cold environments.
6- Extensive physical activity should be avoided 
either before or immediately after meals in epileptic 
patients. 
7-It is better that meals be arranged so that one eats 
three times a day.
8-The patients should eat goat meat instead 
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of eating the meat of large mammals. 
He proposed that goat meat is much drier and thus 
reducing the process of “humidification” in the 
body. 
9-Celery eating, also, should be avoided because it 
excites the epilepsy, whereas coriander is beneficial 
because it inhibits the formation of vapors in the brain. 
10-He recommends abstinence from “fresh fruit 
due to its high water content; the heavier vegetables 
such as cabbage, turnips, and radishes; and any 
food that produces evaporations that could pass 
into the brain” (39-43).
B) Modern period 
In Iran, the first epilepsy diet therapy center as a 
ketogenic diet established by Pediatric Neurology 
pioneer, father of Iranian pediatric neurology, 
Prof. Mohammad Ghofrani, in Shahid Beheshti 
University of Medical Sciences, Mofid Children 
Hospital in 1985 and it is more than 30 years that 
pediatric neurologists in Iran (especially in Mofid 
Children Hospital) administrated KD for children 
with DRE. Now, there are four major academic 
pediatric neurology departments in medical science 
universities of Shahid Beheshti, Tehran, Tabriz 
and Shiraz that have developed KD programs and 
clinics. These centers have been introduced as the 
focal points of “childhood epilepsy KD therapy” 
in the northwest of Iran (Tabriz center), south and 
southwest of Iran (Shiraz center) and remaining 
other regions of country (Shahid Beheshti and 
Tehran centers).Interestingly, epileptic patients 
from other countries such as Azerbaijan and Iraq 
referred to these centers to receive KD therapy, 
representing the significance of these focal points 
in offering services to neighborhood countries. 
Studies conducted in these centers have primarily 
like most similar studies focused on the effects of 
the KD on seizure control and its side effects (44).
Ketogenic Diet
Parisian physicians, Gulep and Marie, introduced 
the first modern use of starvation as a modality for 
epilepsy therapy in 1911 .They treated 20 epileptic 
patients and reported the efficacy of starvation 
in reducing severity of seizures during treatment 
(43). In 1921, Dr. Russell Wilder suggested 
that the fasting induced ketonemia may reduce 
seizure frequency (45).Then, KD developed and 
practitioners have started to administration of 
KD for childhood DRE since 1924 (42). In 1930, 
Barborka treated 100 epileptic adult patients 
with the KD and reported seizure control during 
treatment, either completely or partially, in 56% 
of patients (46).The number of studies on KD 
has increasingly extended during past 40 years 
as more than 100 new KD related articles publish 
each year. Currently, there are four distinct types of 
KD available including (1) the traditional “classic” 
KD;(2) the medium-chain triglyceride (MCT) 
diet,(3) the modified Atkins diet (MAD), and (4)
the low glycemic index treatment (LGIT) (14).
KD studies in Iran
In parallel with increasing use of the KD in the 
other countries, physicians in Iran have started to 
treat patients with the KD and subsequently several 
studies performed about “the role of KD in treatment 
of epilepsy” during past 30 years. We categorized 
these studies into four groups and evaluated them 
based on some results predominantly effectiveness, 
patients’ acceptance and side effects.
1) Classic KD studies
Publications on classic ketogenic diet in either 
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English or Persian (Farsi) languages were identified 
by systematically searching in online databases. A 
total of 8 published papers identified (Table 1). 
The first study that was classically conducted in 
Iran to determine the effectiveness of ketogenic 
diet in epileptic children refractory to medication, 
presented in “The 9th International Child 
Neurology Congress The 7th Asian and Oceanian 
Congress of Child Neurology” at September 
20–25, 2002 Beijing, China by Prof. Mohammad 
Ghofrani, founder of Pediatric Neurology in Iran, 
and published in Brain & Development Journal, 
Volume 24(47). In this study, 215 epileptic children 
treated with KD at Mofid children’s hospital 
between 1989 and 1999. Mean age of the patients 
was 5.1 years (range: 2 to 12 years).The results 
were analyzed after starting classic KD for each 
patient at the end of first and sixth month. Among 
initial registered 215 patients 3, 23 and 92 patients 
left the study at the end of first, sixth and twelfth 
month, respectively.
The results were as the following at the end of first 
month for 212 patients:
(1) Being seizure-free in 144 (67%)
(2) More than 50% reduction in seizure frequency 
in 22 (10.2%)
(3) Less than 50% reduction in seizure frequency 
in 16 (7.5%)
(4) No response to treatment in 30 (14%)
The results were as the following at the end of sixth 
month for 192 patients:
(1) Being seizure-free in 90 (41.8%)
(2) More than 50% reduction in seizure frequency 
in 32 (14.9%)
(3) Less than 50% reduction in seizure frequency 
in 22 (10.3%)
(4) No response to treatment in 48 (22.5%)
The results were as the following at the end of 
twelfth month for 123 patients:
(1) Being seizure-free in 21 (9.8%)
(2) More than 50% reduction in seizure frequency 
in 17 (17.7%)
(3) Less than 50% reduction in seizure frequency 
in 21 (9.7%)
(4) No response to treatment in 64 (31%)
There was no statistically significant relationship 
between “response to treatment” and “follow up 
time”, but there was significant difference between 
“response to treatment” and “reduced number of 
ASDs”48) ).
Later, other neurologists performed several 
researches in the field of classic KD along with 
other types of KD in the all age groups of patients 
with epilepsy (Tables 1, 2 and 3).
In one study, 87 patients with epilepsy treated with 
KD at Mofid children’s hospital between 1999 and 
2006 to evaluate the efficacy and acceptability of 
the classic ketogenic diet. Mean follow-up time 
was 9.4 ± 9.8 SD (range 1-24 months). Only 
children who had DRE or who had severe adverse 
reactions to ASDs were entered to the study. On 
the first day of admission, paraclinic investigations 
such as EEG and laboratory studies were carried 
out. All sugar-containing medications were 
discontinued. Then, the fasting initiated in the 
hospital and continued for 24-72 hours when 4+ 
ketonuria was detected in urine analysis. Later, 
the diet was started at the classic 4:1 ratio (ratio 
of grams of fat to protein plus carbohydrate).
Younger children were started at the lower ratio 
(3:1) to allow more protein intake. Fluids were 
restricted to 75% of maintenance level. Total 
carbohydrate intake was not more than 30 gram and 
not less than 10 gram per day. Prior to discharge, 
mothers had been educated, supplements were 
added and ASDs were reduced. Patients followed 
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up at hospital KD clinic at 1, 3 and 6 months 
after discharge. At the end of the first month, 
seizure frequency reduced to at least 50% in 
71% of patients. At the end of the third month, 
acceptable reduction in seizure frequency (at least 
50%) occurred in 87% of children, of which 39% 
had complete seizure control. At the end of sixth 
month, seizure frequency reduction continued in 
63% of patients (49).This results was identical to 
the previous study in Classic KD in Iran (48).
In another study, 66 children with DRE treated 
with classic KD from October 2008 to June 2010.
Inclusion criteria were as following: 
1) Age between 1and16 years old
2) No neurodegenerative disorders and neoplasm 
of CNS
3) No febrile convulsions
4) the acceptable literacy of parents (at least 
school education).
In the first meeting, the trained dietitian explained 
the ketogenic diet and the goals of the study to 
the family. Then, the parents signed informed 
consent forms and before starting the diet, 
parents were asked to register the frequency 
of their child’s seizures (number of seizures/
day) for a period of one week. The patients were 
 hospitalized in the pediatric neurology ward. 
Fasting and fluid restriction was undertaken when 
3+ to 4+ ketonuria was detected. The patients were 
then fed a single daily meal of a 3:1 ratio. The diet 
gradually increased in amount to provide the total 
daily required calories. High-fat foods provided 
one third of the total daily required calories on 
the first day, two thirds of the required calories on 
the second day and full required calories on the 
third day of treatment. Efficacy was defined as a 
reduction of more than 50% in seizure frequency. 
After 3 months, 80% of the patients kept the diet. 
After one week, one month and 3 months, there 
was a more than 50% reduction in the frequency of 
the seizures in 40 (60%), 50 (75%) and 39 (59%) 
patients, respectively. Three patients (4.5%) were 
seizure-free after 1 week, 12 (18%) were seizure-
free after one month and 12 (18%) were seizure-
free after three months (50).
An open label trial was done to evaluate the 
effects of KD on serum lipid profile. In this study, 
33 children with DRE treated with the KD and 
were followed for 6 months. Their serum lipid 
profile was assessed at baseline. After 6 months 
of administering the diet, median serum levels 
of triglyceride (TG), total cholesterol (Chol), 
low density lipoprotein (LDL) and high-density 
lipoprotein (HDL) were significantly increased. 
However, at 3 and 6 months after initiating the diet, 
seizure frequency was reduced in 63 % of children. 
Results of this study indicated that a classic KD 
in children with refractory seizures is effective 
in seizure reduction, but leads to development of 
hypercholesterolemia and hypertriglyceridemia 
(51).
Another prospective, open-label study was carried 
out to investigate the influence of the KD on liver 
function. A total of 28 children and adolescents with 
DRE who did not respond to at least 2 ASDs enrolled 
the study but half of them left the study. Liver 
function tests including Alanine aminotransferase 
(ALT), Aspartate aminotransferase (AST), and 
alkaline phosphatase (ALP) were measured before 
and after 3 months of starting KD. The serum levels 
of ALP and AST did not differ significantly before 
and after 3 months on the diet, while a significant 
difference identified in the serum level of ALT 
before and after 3 months of treatment (52). 
In a study, the KD effect on the growth of 14 girls 
and 22 boys with DRE evaluated .Mean age of 
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the patients was 4.1 years (range: 2 to 7 years).
Comparison of the studied parameters before the 
initiation of the diet and 3 months later showed 
significantly reduction in weight as well as serum 
levels of hemoglobin, calcium, glucose. Moreover, 
mean height growth velocity of 2.5cm per year was 
lower than normal growth velocity chart for age. 
In conclusion, the results showed that although the 
patients’ height growth velocity did not statistically 
change, their mean weight, and mean serum levels 
of hemoglobin, calcium, and glucose decreased 
significantly. The study, also, showed significant 
increase in the serum levels of Chol, TG, VLDL, 
and LDL/HDL and Chol/HDL (53).
In another study, 43 children with DRE treated with 
classic KD between 2003 and 2005.At the end of 
first, third, sixth and twelfth month, 50% reduction 
in seizure frequency were observed in 77%, 65%, 
44% and 35% of patients54) ).
In another open label trial, to evaluate the efficacy, 
safety, and tolerability of
a classic 4:1 ketogenic diet using a formula-based 
power (Ketocal), 27 infants and children with DRE 
and aged between 12 months and 5 years entered to 
the study. Of 27 children, 5 were lost to follow-up 
and 22 were remained at the end of the study. None 
of these children discontinued the diet because 
of the complications. Thirteen children and their 
parents (59%) reported that the diet was palatable 
and tolerable enough.  After 4 months, the median 
frequency of seizures per week reduced more 
than 50% and 90% in 15 (68.2%) and 6 (27.3%) 
children, respectively. The authors concluded 
that the ketogenic diet using a formula-based 
powder (Ketocal) is effective, safe, and tolerable in 
infants and children with DRE who are reluctant to 
eat homemade foods (55).
2) Modified Atkins Diet (MAD) studies
A total of 3 published papers identified regarding 
modified Atkins diet by systematically searching in 
online databases (Table 2).A clinical trial study was 
conducted in 51 epileptic children aged 1 –16 years 
with DRE  from 2004 to 2006.Among patients,27 
left the study for various reasons and remaining 24 
continued the Atkins diet for a minimum of three 
months. Carbohydrates were initially limited to 10 
g/day and fats constituted 60% of the total energy 
requirement. Following three months of treatment 
with the Atkins diet, 16 patients (67%) had  more 
than 50% reduction in seizure frequency, and 6 
(25%) had more than 90% improvement, of whom 
5 were seizure-free. Mean seizure frequency after 
the first, second and third months of treatment 
were significantly lower than at baseline. Results 
showed that the Atkins diet can be considered as a 
safe and effective alternative therapy for childhood 
DRE .Atkins diet was well tolerated in patients. 
No serious complications were observed during 
the trial; however, in some of the 27 patients who 
left the study, minor side effects such as nausea, 
vomiting, and loss of appetite were the probable 
causes of diet discontinuation (56).
In another study, 21 children in the age range 
of 4-17 years with DRE were treated with the 
Modified Atkins Diet prospectively in a hospital 
based ambulatory clinic between 2006 and 2008. 
These children were experiencing more than four 
seizures per month which could not be controlled 
by any combination of three or more ASDs. 
Patients with evidence of metabolic disorders were 
excluded. Efficacy was evaluated based on the 
comparison between the average monthly baseline 
seizure frequency (3 months before diet initiation) 
and seizure frequency after 6 months of starting 
MAD. Six months after initiating the modified 
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Atkins Diet, 52.4% of the patients remained on 
the diet and 42.9% experienced more than 50% 
reduction in seizures (57).
In a controlled randomized clinical trial, 66 
refractory adult epileptic cases treated with MAD 
from 2010 to r 2012.They were randomly divided 
into two groups:
1) A case group (22 patients): a group that treated 
with both ASDs and MAD. 
2) A control group (32 patients): a group that 
treated only with ASDs.
The primary outcome was at least 50% reduction in 
seizure frequency after 2 months of therapy. Also, 
the study showed that MAD co-therapy in case 
group can decrease seizure frequency 2.19 times 
in comparison with control group. No significant 
difference was shown between groups regarding 
baseline characteristic (58).
3) Low Glycemic Index Treatment (LGIT) studies
In searching of online databases, only one 
published article found regarding Low Glycemic 
Index Diet (LGIT).In this study as a first Middle 
East report about LGIT, 42 children with DRE, 
aged between 1.5 and 17 years treated with LGIT 
from 2009 to 2011. LGIT was initiated on an 
outpatient basis. The diet was composed of 65% 
fat, 25% protein and 10% carbohydrate (40–60 
g), and the glycemic index of foods was limited to 
below 50. At the study entry, 84% of patients were 
categorized as having more than one seizure per 
day, with the remaining children as experiencing 
over one seizure per week. A more than 50% seizure 
reduction was observed in 71.4% of the patients 
after the second week, in 73.8% at the end of the 
first month and in 77.8% at the end of the second 
month. In 30% of the patients a mild increase in 
blood urea nitrogen (BUN) was detected. The ratio 
of fat to carbohydrate and protein grams was 1:1 
with less fat compared to MAD and classic KD. 
Treatment efficacy is not related to the levels of 
ketone yet correlates with lower and steadier blood 
glucose levels. In this study, LGIT had fewer side 
effects when compared to KD, a characteristic that 
is of great value for young children. The study 
showed 12.6% increase in serum triglycerides 
levels without significant metabolic implication. 
Although elevated BUN levels detected in 
approximately one-third of patients that were 
probably the result of protein intake, there is likely 
no relationship between excessive protein intake 
and kidney failure in normal subjects. Therefore, 
it is recommended that LGIT patients followed 
closely up for renal function, higher fluid intake, 
and modifications in protein intake if necessary. In 
conclusion, this study indicated some benefits for 
LGIT as following:
(1) High compliance and better tolerability 
compared with classic KD
(2) LGIT is a safe and effective adjuvant 
antiepileptic therapy and may be used as an 
alternative to the classic KD in conditions 
when this diet cannot be used for any reason 
(3) Easy preparation without detailed meal plans 
and weighing food on a gram scale 
(4) Improved palatability because of more 
liberalized carbohydrate content and decreased fat 
content 
(5) Fewer psychosocial issues as seen in classic 
KD
(6) Ability of the patients to eat outside the home 
without the need to prepare special meals. 
(7) The low cost of the outpatient implementation 
of LGIT was a main benefit (59).
4) Comparative KD studies
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Two papers from Iran have been published to date 
regarding comparison of efficacy of KD types 
with each other or with non dietary treatments 
(Table 3). A clinical trial study performed on 
40 children with DRE between 2005 and 2010. 
The subjects categorized into two groups. Initially, 
20 patients in first group were treated with the 
Atkins diet from January 2005 to October 2007, and 
then 20 patients in the second group treated with 
the classic KD from October 2007 to March 2010. 
At the end of first, second, and third month, more 
than 50% reduction in seizures frequency occurred 
in 55%, 30%, and 70% of patients in the KD group 
and in 50%, 65%, and 70% of cases in the Atkins 
diet group, respectively. The study showed there 
was no significant difference between the classic 
Ketogenic diet and the Atkins diet at the end of 
first, second, and third month and both groups had 
similar responses to the treatment (60).
In another study, 40 children with DRE were 
treated with the classic KD and IVIG in 1995. The 
subjects categorized into two groups. The first 
group treated with classic KD and the second group 
treated with IVIG. Seizure frequency reduced 64% 
and 52% in the first and second group at the end 
of sixth month, respectively. However, difference 
between two groups was not significant (61).
Discussion
A) The basic epidemiologic data and optimized 
epilepsy care services 
1) Why the basic epidemiologic studies are 
important?
Epidemiologic studies conducted regarding to 
the prevalence of epilepsy are more than those of 
incidence in developing countries. Moreover, it is 
generally reported that epilepsy is more prevalent 
in developing than in developed countries (62, 63). 
During the last several decades of the 20th century, 
plenty of studies have been done to determine the 
prevalence of epilepsy in developing countries and 
children (64, 65). The prevalence of epilepsy in 
developed countries ranges from 4 to 10 cases per 
1000 (66).However, higher prevalence of epilepsy, 
ranging from 14 to 57 cases per 1000, have been 
reported in the developing and tropical countries. 
Higher prevalence of epilepsy in the these countries 
is probably due in part to differences in study 
methodology, problems with case ascertainment, 
lack of standardized classification, and  poor 
epilepsy diagnostic accuracy tools (67, 68). On the 
other hand, a variety of epidemiological studies 
of the prevalence of epilepsy in children have 
been done in many countries. In the most studies, 
prevalence reported 4 to 5 per 1,000 children, 
or about 0.5 percent. Also, studies indicated that 
the prevalence increases with age, ranging from 
approximately 2-3/1000 to 4-6/1000 in  7 and 11-
15 year olds, respectively (65).
Because epilepsy is a heterogeneous disorder, 
study of simple prevalence and incidence do not 
demonstrate many aspects of the condition’s 
characteristics including “response to variety 
of pharmacological and non pharmacological 
treatments” in a general population (68). Besides 
the incidence and prevalence, epidemiological data 
provide knowledge about and potential risk factors 
for epilepsy, and can be used for planning health 
services including development of “organized 
epilepsy unites” in the hospitals, especially “KD 
clinics” for people with DRE(32).
According to the WHO, nearly 80% of the people 
with epilepsy living in developing countries receive 
no treatment at all (69).In a review performed to 
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the evaluation of a proportion of epileptic patients 
receive no care ( a “treatment gap” ), demonstrated 
that 75% of epileptic people with treatment gap 
live in low-income countries(70). As a result, 
they expected to have more “epilepsy induced 
morbidity  and psychosocial consequences”, while 
in the most of them completely control of epilepsy 
is not impossible and they can return to a normal 
life by taking an appropriate care provided there 
were an essential epidemiologic data (71).
2) How many national epidemiologic studies have 
been done for epilepsy in Iran?
In searching of online databases, there were a few 
published articles regarding national epidemiology 
of epilepsy in Iran. In a study with population size 
of 35014, estimated crude prevalence (per 100 
persons) was 12 (72).In another epidemiologic 
study, the prevalence of epilepsy was 1.8% and it 
was more common in females, unemployed people 
and higher educational level. Authors concluded 
that the lifetime prevalence of epilepsy in Iran is 
not low (73). In a meta-analysis and systematic 
review study, the prevalence of epilepsy in Iran 
estimated nearly 5%, a result that surprisingly was 
much higher than reported prevalence in other 
countries (8).
3) What is the prevalence of epilepsy in neighborhood 
and similar countries to Iran?
Asian studies documented a prevalence of 2.2 per 
1000 persons in India (1,74-76). The crude prevalence 
rate of epilepsy was 9.98 per 1000 persons in Pakistan 
and 7.0 per 1000 persons in Turkey. In both 
countries the prevalence was roughly twice as 
high in rural compared to urban areas (12,77). 
Lifetime prevalence of 7.0 per 1000 persons has 
been reported in China (78). An approximate 
724,500 people with epilepsy live in the Arab 
world. An incidence of 174 per 100,000 persons 
in 2001 was reported in a hospital-based 
study from Qatar. Prevalence ranged between 
0.9/1,000 in Sudan and 6.5/1,000 in Saudi Arabia, 
with a median of 2.3/1,000. All the studies report 
higher prevalence in males, which was statistically 
significant in the Saudi study (79). 
The incidence of epilepsy in children ranges from 
41- incidence is consistently reported to be highest 
in the first year of life and declines to adult levels 
by the end of the first decade. The prevalence of 
epilepsy in children is consistently 187/100,000. 
Higher incidence is reported from underdeveloped 
countries. The incidence is higher than and ranges 
from 3.2-5.5/1,000 in developed countries and 
3.6-44/1,000 in underdeveloped countries. Either 
prevalence or incidence seems highest in rural 
areas (79 - 81).
3) What is the conclusion?
In almost all the Middle East countries, mental 
health units in ministries of health are also 
planning and implementing for epilepsy. In the 
Islamic Republic of Iran, the health information 
system, which includes mental disorders, also 
encompasses epilepsy (32).Therefore, in order 
to develop national and adapted models for the 
promotion of epilepsy control including initiation 
of advanced epilepsy centers with KD clinics and 
reduce the treatment gap and social and physical 
burden, it is important that Iranian ministry of 
health, neurology associations, academic university 
experts and other related practitioners cooperate to 
do essential studies especially epidemiologic ones 
and subsequently use their results information to 
planning epilepsy care services.
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B) Comparison of ketogenic diets’ studies between 
Iran and other countries
As tables 1, 2 and 3 showed, a total of 14 researches 
have been done in the field of KD and epilepsy – 
most of which (57%) are about classic KD- since 
1989.In these studies, researchers evaluated several 
features of KD including effects, tolerability, side 
effects and acceptance. Also, as mentioned earlier, 
there are four active KD clinics in Iran offering 
services to children with DRE, while more than 
150 centers outside of the USA and 100 centers 
inside the USA(83) provide the ketogenic diet 
programs (81, 82).In this review, approximately 
all Iranian studies reported that KD, either 
classic KD or MAD and LGID, were effective 
in treatment of epileptic children and adults with 
minimal side effects. With availability of Medline 
in 1965, more than 900 human studies of dietary 
therapies for epilepsy have been published to date 
(83). Approximately 100 new articles concerning 
epilepsy dietary therapy are being published each 
year. Although initiation and management of the 
KD around the world are different, the benefits are 
similar (84). Hundreds of studies over the past two 
decades have shown significantly results identical 
to Iranian studies (14).In almost all studies, a 
conclusion have been similar: approximately 50–
60% of children will have at least more than 50% 
seizure reduction, with one third have more than 
90% response (85-87).
Several studies with retrospective, prospective and 
Meta analyses methodologies have indicated the 
efficacy of KD in intractable childhood epilepsies 
(88 -92). In a Cochrane review based Meta analyses 
of four randomized controlled studies (93-96), the 
efficacy of KD on epilepsy was confirmed in 289 
children and adolescents (97). A meta-analysis of 
19 studies including a total of 1084 children showed 
more than 90% seizure reduction in one-third of 
patients and more than 50% seizure reduction in 
half of the patients (92).A large prospective KD 
study including 150 children with DRE, represented 
50-90% seizure reduction in 26% of children and 
90% seizure reduction in 31% of children (98). 
A Chinese KD study including 317 children with 
DRE, showed more than 50% seizure reduction in 
35%, 26.2%, and 18.6% of children after 3, 6 and 
12 months, respectively (99). 
A recent meta-analysis of studies from 1925 to 
1998 reports that 30% of patients have a 50% to 
90% reduction in seizures and an additional 37% 
of patients have more than a 90% reduction in 
seizures (100).
In an Indian prospective study of 27 children with 
DRE, more than 50% seizure reduction occurred in 
48% of patients at 6 months and, more than 50% 
seizure reduction occurred in 37% of patients at 12 
months (101). KD is shown to be more effective 
than most ASDs and to reduce seizure frequency at 
least by 50% in half of the patients (102).Also, it 
is shown that recurrence rate of seizures is reduced 
after discontinuation of KD (103). It seems that 
efficacy with the KD does not decrease over the 
years, and seizure control continues many years 
later, surprisingly even after the KD has been 
discontinued (104,105). 
The first formal, prospective, open-label study of 
MAD was designed and 20 children with DRE 
were treated (106).Also, the benefits of the MAD 
confirmed in two studies from Korea (107,108).
In a randomized controlled study of the MAD for 
the treatment of childhood epilepsy, the likehood 
of more than 50% and 90% seizure reduction was 
higher compared to the control group of standard 
medical management (109). In a study from Korea, 
14 children with DRE evaluated in terms of the 
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efficacy, safety, and tolerability of MAD. At 6 
months, more than 50% seizure reduction occur in 
patients (106).
The only study from Iran suggested that 
LGIT could reduce seizure frequency in a 
large number of patients with DRE (60). The 
first study of LGIT was published in 2005 with 
promising results. In a study, authors reported more 
than 50% reduction in up to 66% of the patients 
compared to baseline seizure frequency after 12 
months (110).
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